First-line chemotherapy plus immunotherapy in biliary tract cancer
- PMID: 35278357
- DOI: 10.1016/S2468-1253(22)00052-8
First-line chemotherapy plus immunotherapy in biliary tract cancer
Conflict of interest statement
CN provided consultancy or received honoraria from Amgen, AstraZeneca, Baxter, Bristol-Myers Squibb, Fresenius Kabi, Incyte Biosciences, Merck, MSD, Viatris, Novartis, Nutricia, Pierre Fabre, Roche, Sanofi, and Servier; and received research funding from Roche. CN was coordinating investigator of clinical trials that received funding from OSE Immunotherapeutics, AstraZeneca, Fresenius Kabi, Nutricia.
Comment on
-
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532. doi: 10.1016/S2468-1253(22)00043-7. Epub 2022 Mar 9. Lancet Gastroenterol Hepatol. 2022. PMID: 35278356 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources